Better Bull Market Buy: Novavax vs. Pfizer
It's official: The S 500 is in a bull market after reaching a new all-time high last month. The index actually has been in this positive market phase ever since it started recovering from its bear market low about 16 months ago -- and since bull markets generally last longer than bear markets, investors should have plenty of time to benefit from this one.
How to get the most out of a bull market? By investing in stocks with solid growth prospects. That's because these environments usually support growth companies as well as those that are ramping up for a new wave of growth ahead. Today, the market offers plenty of opportunities, but Motley Fool contributors Adria Cimino and Keith Speights have zeroed in on two compelling healthcare players: biotech company Novavax (NASDAQ: NVAX) and big pharma (NYSE: PFE). So which makes the better bull market buy now?
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
Überwältigendes Buy-Interesse bei Pfizer Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Pfizer Inc. mit einem Kursziel von 41 € im Vergleich zum aktuellen Kurs von 26.64 € zu erwarten.
